Nephro-protective effects of alpha-lipoic acid in type I diabetes.

Autor: Kushwaha K; Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, India., Mandal D; Department of Botany, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, India., Khurana N; Department of Pharmacology, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India., Gupta J; Department of Biochemistry, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, India.
Jazyk: angličtina
Zdroj: Journal of biochemical and molecular toxicology [J Biochem Mol Toxicol] 2024 Apr; Vol. 38 (4), pp. e23712.
DOI: 10.1002/jbt.23712
Abstrakt: Type 1 diabetes (T1D) is an insulin-dependent autoimmune condition. Short chain fatty acids (SCFAs) are volatile fatty acids with 1-6 carbon atoms that influence glucose storage in the body and can reduce appetite, potentially decreasing T1D risk. Alpha-lipoic acid (α-LA), a type of SCFA, has previously been used to treat diabetic neuropathy and inflammation due to its antioxidant properties. This study aims to assess α-LA's protective effects against T1D and associated kidney damage in rats induced with streptozotocin. Diabetic rats were treated with α-LA orally for 15 days, resulting in improved blood glucose (56% decrease) and kidney function markers like blood urea nitrogen, creatinine and uric acid. α-LA also showed significant antioxidant effects by decreasing LPO as well as improving activities of antioxidant enzymes like superoxide dismutase, catalase and glutathione-S transferase and alleviated kidney damage caused by diabetes. Docking experiments suggest that α-LA may regulate diabetes-related changes at the epigenetic level through interactions with the SIRT1 protein, indicating its potential as a target for future antidiabetic drug development.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: